| Shalini Mehta, MD | |
|
3600 Nw Samaritan Dr, Corvallis, OR 97330-5472 | |
| (541) 768-5111 | |
| Not Available |
| Full Name | Shalini Mehta |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 10 Years |
| Location | 3600 Nw Samaritan Dr, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093126757 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Samaritan Pacific Community Hospital | Newport, OR | Hospital |
| Samaritan Albany General Hospital | Albany, OR | Hospital |
| Samaritan Lebanon Community Hospital | Lebanon, OR | Hospital |
| Samaritan North Lincoln Hospital | Lincoln city, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Good Samaritan Hospital Corvallis | 1557270725 | 339 |
News Archive
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
In a recently published study, providing advice over a 5-year period about leading a healthy lifestyle reduced the risk of heart-related deaths over the next 40 years.
States are grappling with the realities of the health law: Illinois is using social media to field consumer worries over the rollout of the law even as the law brings more money - and more stress - to the state. In the meantime, the differences between exchange launches in Washington state and Oregon are examined.
A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.
› Verified 2 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20031111000297 |
News Archive
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
In a recently published study, providing advice over a 5-year period about leading a healthy lifestyle reduced the risk of heart-related deaths over the next 40 years.
States are grappling with the realities of the health law: Illinois is using social media to field consumer worries over the rollout of the law even as the law brings more money - and more stress - to the state. In the meantime, the differences between exchange launches in Washington state and Oregon are examined.
A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.
› Verified 2 days ago
| Entity Name | Good Samaritan Hospital Corvallis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453134 PECOS PAC ID: 1557270725 Enrollment ID: O20031125000163 |
News Archive
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
In a recently published study, providing advice over a 5-year period about leading a healthy lifestyle reduced the risk of heart-related deaths over the next 40 years.
States are grappling with the realities of the health law: Illinois is using social media to field consumer worries over the rollout of the law even as the law brings more money - and more stress - to the state. In the meantime, the differences between exchange launches in Washington state and Oregon are examined.
A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.
› Verified 2 days ago
| Entity Name | Albany General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372340 PECOS PAC ID: 9931097987 Enrollment ID: O20040310000310 |
News Archive
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
In a recently published study, providing advice over a 5-year period about leading a healthy lifestyle reduced the risk of heart-related deaths over the next 40 years.
States are grappling with the realities of the health law: Illinois is using social media to field consumer worries over the rollout of the law even as the law brings more money - and more stress - to the state. In the meantime, the differences between exchange launches in Washington state and Oregon are examined.
A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.
› Verified 2 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20061104000140 |
News Archive
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
In a recently published study, providing advice over a 5-year period about leading a healthy lifestyle reduced the risk of heart-related deaths over the next 40 years.
States are grappling with the realities of the health law: Illinois is using social media to field consumer worries over the rollout of the law even as the law brings more money - and more stress - to the state. In the meantime, the differences between exchange launches in Washington state and Oregon are examined.
A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shalini Mehta, MD Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Shalini Mehta, MD 3600 Nw Samaritan Dr, Corvallis, OR 97330-5472 Ph: (541) 768-5111 |
News Archive
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
In a recently published study, providing advice over a 5-year period about leading a healthy lifestyle reduced the risk of heart-related deaths over the next 40 years.
States are grappling with the realities of the health law: Illinois is using social media to field consumer worries over the rollout of the law even as the law brings more money - and more stress - to the state. In the meantime, the differences between exchange launches in Washington state and Oregon are examined.
A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.
› Verified 2 days ago
Tomer Pelleg, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3600 Nw Samaritan Dr Ste 227, Corvallis, OR 97330 Phone: 541-768-1261 | |
Dr. Parinav Kanwar, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Dr. Stanley J. Nudelman, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3521 Nw Samaritan Dr, Suite 201, Corvallis, OR 97330 Phone: 541-768-5140 | |
Dr. Randall V. Bream, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3600 Nw Samaritan Dr, Suite E350, Corvallis, OR 97330 Phone: 541-768-5205 Fax: 541-768-5206 | |
Jonathan David Jones, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3620 Nw Samaritan Dr Ste 202, Corvallis, OR 97330 Phone: 541-768-5800 | |
Gemechu Abraham Geleto, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Roland Solensky, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 |